Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

Researchers at the University of Oklahoma have developed a breakthrough method of adding a single nitrogen atom to molecules, ...

Over a video call, Alex Zhavoronkov holds up a small, green, diamond-shaped pill. It has been developed by his company to ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

This article provides examples of how AI is helping to shape drug discovery, from drug design through to clinical trials.

Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...

Susan Sharfstein, a professor at UAlbany's College of Nanotechnology, Science and Engineering, partners with DeepSeq.AI on a ...

Drug pricing is influenced by numerous factors, but technology has the potential to strike the critical balance between ...